Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.
about
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialOutcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trialOutcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhoPostrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupMeta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemiaChildhood acute lymphoblastic leukaemia and relapse.Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocolRelapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UKNovel Bruton's tyrosine kinase inhibitors currently in development.Childhood leukaemia: long-term excess mortality and the proportion 'cured'.Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.Improving outcomes for high-risk ALL: translating new discoveries into clinical care.Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia.Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Extramedullary Relapse of Acute Myeloid and Lymphoid Leukemia in Children: A Retrospective Analysis.Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.[Treatment of children and adolescents with relapsed ALL: therapy target long-term healing].DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia.Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions.
P2860
Q24621523-CCD3F398-887D-47E1-B287-B02269339141Q28543517-B0C3B776-5744-48E4-8ADD-3733AE5BD360Q33628794-46A8870F-3B28-46C1-974B-39EC69FBD66BQ33647130-C4DA2D7B-8593-4D0F-ADB7-CC8B9D7F1E2EQ33711119-B53E5891-28AC-4F64-9F36-FA41355C84FDQ34052660-63C7CF71-BFCE-4B3A-8D15-3E575CE55D57Q34547528-A264BE77-AF22-411B-9FCF-4839A835AB38Q34707213-A1677E6F-6E4D-49F5-AB35-1835C410D6AFQ35848913-9A06127F-8B4A-4D6B-8D22-C6F7C8E2E30EQ35953635-048A8096-30FB-497E-8F4F-3ECEC730C29BQ36276060-76862A4A-98DC-4CEC-9F67-D97D677E3AD6Q36340652-5D04C003-A204-4588-869C-F0F1641CB913Q36366644-71B5BE92-F0B4-4C92-908B-132183C2F8AFQ36420748-FBF25B11-F5C5-4B01-8430-5B9394CBF8F8Q36610199-971B513E-6AD6-4989-815E-24B4335C131EQ36673755-1DCC4017-B58A-4C2A-833F-496DD984241BQ36755145-823237B5-2A4D-43F2-9182-BBA516290486Q37124911-5F7F8F1E-6DBE-496C-A619-49480EED44FCQ37126126-8F7919DC-0B2B-41D2-A1F4-D198F107045AQ37352480-5536E710-B381-4705-A11F-D847AD989C50Q37677743-F1A458AA-B3AA-42CF-A90F-8F0FFB4ADD2BQ37788239-A0C09338-5B25-42D1-B125-61524C32F3C5Q37849259-9CBF2678-CCA9-4B80-A1CF-33F5DB41A5AFQ37952302-717232F3-C02D-48EA-B54A-E445ADBA3012Q38066860-059DFE35-2BDC-4336-B626-F1572C6629CCQ38097334-3A233486-E5FA-4A19-AE3D-907908D5B5F9Q41505498-2669DDF2-9673-4819-A70A-4FE22B277F4DQ41976584-60E1311D-8A0E-4EBB-9F8C-97A2DF2360CAQ42544058-D943AA78-8F53-4E01-82FE-03665622E27AQ46129905-F2ECCCC4-6B70-43BF-B6AB-01CC7916A2FAQ46134516-2482598A-BF3A-4C4F-92E8-73C84174F539Q52887374-B695F860-9F2A-41EF-AB6D-2C14B2A055E8Q55229784-F153D4C2-F129-4B73-902B-AE1944DB5D7BQ55346725-7A6FA16F-5E79-4AAF-B723-8DA7AFF17F04
P2860
Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@en
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@nl
type
label
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@en
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@nl
prefLabel
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@en
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@nl
P2093
P2860
P1476
Outcome after first relapse in ...... m the United Kingdom R2 trial.
@en
P2093
Anindita Roy
Anna Cargill
Anthony V Moorman
Donna Lancaster
Phil J Darbyshire
Sara Stoneham
P2860
P356
10.1111/J.1365-2141.2005.05572.X
P407
P577
2005-07-01T00:00:00Z